Latest ArticlesGlucagon-like peptide-1 receptor agonist (GLP-1RA) is an important hypoglycemic agent, which has various metabolic effects. It plays an important role in reducing body mass and treating complications of diabetes mellitus type 2 (T2DM). In terms of efficacy, GLP-1RA had a proportion of adverse responses, including baseline glycosylated hemoglobin, islet beta cell function, GLP-1RA drug dose, body mass index, ethnicity or predictable partial glycaemia response. In terms of tolerance, most GLP-1RA tolerance was negatively correlated with the course of treatment. The comprehensive management of T2DM requires patient-centered individualized treatment. This paper summarized the baseline characteristics related to glucose response and tolerance in the treatment of T2DM by GLP-1RA, and explored the appropriate population characteristics for GLP-1RA, in order to provide some reference for clinical medication.
Explore the working pattern of pharmaceutical security in tertiary general hospital during the period of corona virus disease 2019. Establish a ''four-in-one'' matrix of parent hospital, designated hospital, square cabin hospitals, and internet hospital. While ensuring the supply of basic medicines, explore the model of pharmaceutical care, realize the transformation of patient-centered pharmaceutical care, and ensure the medication safety of patients.
Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a novel hypoglycemic agent with a variety of targets. It is widely used in the treatment of diabetic nephropathy (DN), which is characterized by improving oxidative stress and anti-inflammatory effects, alleviating damage of advanced glycosylation end-products, regulating renin-angiotensin-aldosterone system, improving endothelial function, alleviating renal fibrosis, and playing a protective role in the kidney. This paper reviewed the literatures published in recent years on the clinical application and mechanism of GLP-1RA in the treatment of DN, so as to provide reference for clinical practice.
Diabetic nephropathy (DN) is a chronic microvascular complication of diabetes mellitus (DM), which is also the main cause of end-stage renal disease (ESRD). The prevalence rate of DM related chronic kidney disease (CKD) has exceeded that of glomerulonephritis (GN) related CKD. DN has become a big social problem for Chinese residents. The main treatment options for DN are lifestyle change and drug therapy, but currently common drugs can only reduce symptoms and delay disease progression, and new drugs are needed to improve the overall outcome of DN patients. Endothelin receptor antagonist (ERA), a new class of drugs used in DN in recent years, has shown good effects. This article summarized the clinical research progress of ERA in the treatment of DN, aiming to provide reference for clinical practice.
Over activation of mineralocorticoid receptor (MR) can lead to the progression of chronic kidney disease (CKD). Finerenone, a novel MR antagonist with a non-steroidal structure, which is able to bind to MR with a unique mechanism to inhibit the recruitment of transcriptional cofactors involved in gene expression. It can effectively delay the progression of diabetic nephropathy (DN). This article reviewed the mechanism of action, evidence- based evidence, adverse reactions, combined application with sodium-glucose linked transporter-2 inhibitor of the novel finerenone in the treatment of DN, and its future prospects. The aim is to provide a new strategy for clinical treatment of DN.
Sodium-glucose linked transporter 2 inhibitor (SGLT-2i) is a new type of oral hypoglycemic agents. They can lower blood pressure, reduce uric acid, reduce body weight and reduce cardiac and renal adverse events by promoting urinary glucose and sodium excretion in renal tubules. SGLT-2i is one of the hot topics in the treatment of diabetes mellitus (DM) in recent years, which can effectively delay the progression of diabetic nephropathy (DN). This article reviewed the mechanism of action, clinical benefits, safety and guideline update of SGLT-2i in the treatment of DN, in order to provide new strategies for clinical treatment.
Diabetic nephropathy (DN) is one of the most common complications in patients with diabetes mellitus (DM), which is mainly treated by medication in clinic. Oral hypoglycemic agents can not only optimize blood glucose control and reduce the risk of hypoglycemia, but also affect the progression of DN. Among them, dipeptidyl peptidase-4 inhibitor (DPP-4i) is an oral hypoglycemic agent that plays a role in changes in the level of the incretin system. DPP-4i showed additional pleiotropic effects in vitro models, including reduced inflammation, fibrosis and oxidative damage, further indicating a potential renal protective effect. DPP-4i may help delay DN progression, but further studies are needed to prove their specific benefit to the kidney. This article reviewed the biological function of DPP-4i, the mechanism on DN, and the clinical efficacy, in order to provide new ideas for clinical treatment.
To investigate the ameliorative effect of zanthoxylin on inflammatory pain and its regulatory mechanism.
The general pain model and formaldehyde pain model of Kunming mice were established, and the effects of zanthoxylin on the two pain models were compared. The number of autonomous activities of the two model mice was recorded, and the levels of inflammatory factors were detected. The inhibitory effect of α7 nicotinic acetylcholine receptorα(7nAChR) antagonist on analgesia of zanthoxylin was analyzed, and the changes of JAK2 and STAT3 protein expression after α7nAChR antagonist blocking zanthoxylin were determined by western blotting.
In the general pain model, the pain threshold of mice increased from (17.2±4.8) s to (30.3±9.2) s, and the increase rate increased from (43.3±1.3)% to (161.5±8.9)% 1 h after injection of zanthoxylin. The pain threshold of mice was increased from (15.8±5.4)s to (30.6±7.5)s, and the increase rate was increased from (31.7±2.5)% to (158.7±9.8)% 2 h after injection of zanthoxylin. In the formaldehyde-induced pain model, there was no significant difference in the duration of foot licking behavior between the control group and the zanthoxylin group in the phase Ⅰ acute pain stage, but the duration of foot licking behavior in the phase Ⅱ chronic pain stage was shortened in a dose-dependent manner. After the injection of zanthoxylin, the number of spontaneous activities of the general pain model mice decreased from (198.2±71.8) times to (102.0±48.5) times, while the number of spontaneous activities of the formaldehyde nociceptive pain model decreased from (207.5±80.1) times to (110.5±40.8) times. The expression levels of tumor necrosis factor (TNF)-α and interleukin (IL)-6 in the two pain model mice decreased and the expression level of IL-10 increased in a dose-dependent manner after injection of zanthoxylin. The protein expression levels of JAK2 and STAT3 were up-regulated.
Zanthoxylin can increase the pain threshold, shorten the duration of pain behavior and reduce the number of autonomous activities in mice. Its regulatory mechanism may be zanthoxylin binds to the α7nAChR receptor, and then activate JAK2/STAT3 signaling pathway to exert analgesic and anti-inflammatory effects.
To evaluate the effect of Maxing Shigan Decoction assisted western medicine treatment on peripheral blood T helper cell 17/regulatory T cell (Th17/Treg) balance in elderly patients with multi-drug-resistant bacteria (MORDs) hospital-acquired pneumonia (HAP), and provide strong evidence-based medical support for its clinical application.
A total of 130 elderly patients with MDROs-HAP in the respiratory emergency department and ICU inpatient department of our hospital from July 2019 to April 2021 were selected as the research objects and randomly divided into study group and control group, with 65 cases in each group. The control group was given standard Western medicine treatment, and the research group was supplemented with maxing Shigan decoction on the basis of standard Western medicine treatment. The percentage of Th17 (Th17%) and Treg (Treg%), Th17/Treg ratio, the levels of serum interleukin-17 (IL-17), IL-6, IL-10, C-reactive protein, procalcitonin (PCT) in 2 groups were detected. The clinical efficacy and incidence of adverse reactions were compared between the two groups.
After treatment, the levels of serum PCT, IL-6, IL-17, Th17%, Th17/Treg ratio, total traditional chinese medicine syndrome score and acute physiology and chronic health evaluation scoring system Ⅱ in study group were all lower than those before treatment or in control group, while the level of serum IL-10 was higher than that before treatment and the control group (P<0.05). The curative effect of TCM syndrome in study group was better than that in control group (73.85% vs 52.31%, χ2=6.474, P=0.011). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).
Maxing Shigan Decoction can significantly improve Th17/Treg cell imbalance and immune dysfunction in elderly patients with MDROs-HAP, and significantly reduce the level of serum inflammatory factors, so as to effectively and safely improve the clinical efficacy of patients, worthy of clinical promotion.
To observe the effect of Chunru gel combined with policresulen solution on vaginal microecology and inflammatory factors in patients with chronic cervicitis.
A total of 246 patients with chronic cervicitis admitted to Northwest Women's and Children's Hospital from November 2018 to October 2021 were divided into control group and test group according to the simple randomization method, with 123 cases in each group. The control group was treated with policresulen solution, and the test group was treated with Chunru gel on the basis of the control group for four consecutive weeks. The total effective rate of the two groups was compared. The levels of inflammatory factors, vaginal micro ecological indicators and adverse reactions in the two groups were observed before and 4 weeks after treatment.
After 4 weeks of treatment, the total effective rate of the test group was 95.93%, higher than 85.37% of the control group (P<0.05). Serum tumor necrosis factor-β and interleukin (IL)-17 levels of the test group were all lower than those of the control group (P<0.05), and IL-23 levels was higher than that of the control group (P<0.05). The abnormal cleanliness of vaginal microecology, the positive rate of hydrogen peroxide and the positive rate of leukocyte lipase in the two groups were lower than those before treatment, and the test group was lower than the control group, the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).
Chuangru gel combined with policresulen solution has a significant effect on the treatment of chronic cervicitis, which can reduce inflammatory response and improve vaginal microecological indicators.